Table 2.
Patient, infection, and hospital characteristics pre- and post-propensity score matches
| Unmatched sample | 1:1 PSM sample | SDa | |||
|---|---|---|---|---|---|
| Colistin | βL + βLI agent | Colistin | βL + βLI agent | ||
| n = 319 | n = 657 | n = 256 | n = 256 | ||
| Patient | |||||
| Age, mean ± SD | 58.7 ± 17.4 | 61.2 ± 15.6 | 59.7 ± 16.8 | 59.2 ± 15.2 | 3% |
| Sex | |||||
| Female | 136 (43%) | 283 (43%) | 102 (40%) | 106 (41%) | 3% |
| Male | 183 (57%) | 374 (57%) | 154 (60%) | 150 (59%) | 3% |
| Race | |||||
| White | 254 (80%) | 462 (70%) | 198 (77%) | 194 (76%) | 4% |
| Non-White | 65 (20%) | 195 (30%) | 58 (23%) | 62 (24%) | 4% |
| Payer type | |||||
| Commercial | 32 (10%) | 92 (14%) | 28 (11%) | 20 (8%) | 11% |
| Medicaid | 55 (17%) | 112 (17%) | 45 (18%) | 49 (19%) | 4% |
| Medicare | 222 (70%) | 434 (66%) | 174 (68%) | 178 (70%) | 3% |
| Other | 10 (3%) | 19 (3%) | 9 (4%) | 9 (4%) | 0% |
| CCI, mean ± SD | 2.68 ± 2.22 | 2.75 ± 2.29 | 2.63 ± 2.14 | 2.76 ± 2.08 | 6% |
| CCI categories | |||||
| Renal disease (CCI) | 56 (18%) | 140 (21%) | 45 (18%) | 49 (19%) | 4% |
| Diabetes w/complications (CCI) | 86 (27%) | 182 (28%) | 68 (27%) | 70 (27%) | 2% |
| Diabetes w/o complications (CCI) | 34 (11%) | 106 (16%) | 30 (12%) | 32 (13%) | 2% |
| Chronic pulmonary disease (CCI) | 153 (48%) | 215 (33%) | 115 (45%) | 118 (46%) | 2% |
| Hospitalization in prior 30 days | 97 (30%) | 206 (31%) | 75 (29%) | 85 (33%) | 8% |
| ICU prior to 1st dose | 164 (51%) | 283 (43%) | 133 (52%) | 139 (54%) | 5% |
| Exposure ARF drugs prior to 1st dose | 271 (85%) | 564 (86%) | 218 (85%) | 224 (88%) | 7% |
| ARF in Prior 3 months | 42 (13%) | 116 (18%) | 36 (14%) | 35 (14%) | 1% |
| Ventilator prior to 1st dose | 169 (53%) | 222 (34%) | 129 (50%) | 132 (52%) | 2% |
| Sepsis present on admission | 172 (54%) | 333 (51%) | 140 (55%) | 140 (55%) | 0% |
| Index infection | |||||
| Infection site | |||||
| Blood | 20 (6%) | 59 (9%) | 16 (6%) | 15 (6%) | 2% |
| IAI | 1 (0.3%) | 9 (1%) | 0 (0%) | 0 (0%) | – |
| Other | 18 (6%) | 64 (10%) | 17 (7%) | 16 (6%) | 2% |
| Respiratory | 207 (65%) | 195 (30%) | 152 (59%) | 152 (59%) | 0% |
| Skin | 21 (7%) | 120 (18%) | 20 (8%) | 17 (7%) | 5% |
| Urine | 52 (16%) | 210 (32%) | 51 (20%) | 56 (22%) | 5% |
| Pathogen | |||||
| Enterbacterales | 82 (26%) | 257 (39%) | 72 (28%) | 80 (31%) | 7% |
| Non-fermenter | 236 (74%) | 389 (59%) | 183 (71%) | 175 (68%) | 7% |
| Other G-bacteria | 1 (0.3%) | 11 (2%) | 1 (0.4%) | 1 (0.4%) | 0% |
| Carbapenem susceptibility | |||||
| Not susceptible | 225 (71%) | 489 (74%) | 184 (72%) | 179 (70%) | 4% |
| Not tested | 18 (6%) | 44 (7%) | 14 (5%) | 20 (8%) | 9% |
| Susceptible | 76 (24%) | 124 (19%) | 58 (23%) | 57 (22%) | 1% |
| Hospital | |||||
| Bed size | |||||
| < 300 | 107 (34%) | 171 (26%) | 86 (34%) | 86 (34%) | 0% |
| 300–499 | 97 (30%) | 149 (23%) | 73 (29%) | 74 (29%) | 1% |
| 500+ | 115 (36%) | 337 (51%) | 97 (38%) | 96 (38%) | 1% |
| Teaching facility | 156 (49%) | 406 (62%) | 128 (50%) | 130 (51%) | 2% |
| Region | |||||
| Midwest | 99 (31%) | 245 (37%) | 86 (34%) | 93 (36%) | 6% |
| Northeast | 29 (9%) | 45 (7%) | 21 (8%) | 25 (10%) | 5% |
| South | 174 (55%) | 325 (49%) | 133 (52%) | 126 (49%) | 5% |
| West | 17 (5%) | 42 (6%) | 16 (6%) | 12 (5%) | 7% |
| Location | |||||
| Rural | 65 (20%) | 48 (7%) | 40 (16%) | 37 (14%) | 3% |
| Urban | 254 (80%) | 609 (93%) | 216 (84%) | 219 (86%) | 3% |
ARF acute renal failure, CCI Charlson Comorbidity Index, IAI intra-abdominal infection, ICU intensive care unit, SD standard deviation
aAbsolute standardized difference for 1:1 propensity score-matched sample